September 26, 2023 11:37 AM EDTUpdated September 30, 12:59 AM

Novo Nordisk forms cardiometabolic drug discovery accelerator to get to research faster

Kyle LaHucik

Senior Reporter

Novo Nordisk is now tapping into earlier stages of cardiometabolic research by bringing together academic institutions and German drug discovery shop Evotec after it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novo Nordisk forms cardiometabolic drug discovery accelerator to get to research faster

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

No­vo Nordisk forms car­diometa­bol­ic drug dis­cov­ery ac­cel­er­a­tor to get to re­search faster

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Novo Nordisk forms cardiometabolic drug discovery accelerator to get to research faster